ALNY up +2.77% percent Today $ALNY High is at 99.8
Post# of 99
Posted On: 11/10/2014 12:32:23 PM
ALNY up +2.77% percent Today $ALNY High is at 99.87 and the Low 95.84 with current volume of 342,310.
Recent News posted below.
Alnylam Pharmaceuticals ALNY other info.
http://investorshangout.com/Alnylam-Pharmaceu...LNY-53281/
ALNY Alnylam Pharmaceuticals Recent Headline News
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 324.30 (+3.55), ALNY: 99.33 (+3.49), ISIS: 46.25 (+1.66), OGXI: 2.15 (-0.03), TEVA: 58.03 (+0.33), RGLS: 22.84 (+0.76), GSK: 45.17 (+0.26), SNY: 46.34 (+0.65)
Alnylam to Webcast Presentation at the Credit Suisse 2014 Healthcare Conference
Business Wire - Thu Nov 06, 3:00PM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014 at 3:00 p.m. MST (5:00 p.m. EST) at the Arizona Biltmore in Phoenix, Arizona.
ALNY: 99.33 (+3.49)
Alnylam's Q3 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 11:40AM CST
Alnylam (ALNY) reported third-quarter 2014 loss of 58 cents per share, much wider than the year-ago loss of 48 cents per share.
BIIB: 324.30 (+3.55), ALNY: 99.33 (+3.49), AMAG: 34.54 (-0.41)
Investing in Socially Responsible Companies: Alnylam Pharmaceuticals, Inc.
Selena Maranjian, The Motley Fool - Motley Fool - Thu Nov 06, 9:22AM CST
Source: Alnylam Pharmaceuticals. Being a socially responsible company is not a zero-sum game, where the more socially responsible you are, the worse your financial performance is, and vice versa. Profits don't go out the window when you treat the...
ALNY: 99.33 (+3.49)
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 99.33 (+3.49), AMGN: 162.32 (+2.07), SNY: 46.34 (+0.65), REGN: 383.41 (+5.57)
Alnylam beats Street 3Q forecasts
Automated Insights - Wed Nov 05, 5:04PM CST
CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Wednesday reported a loss of $44 million in its third quarter.
ALNY: 99.33 (+3.49)
Alnylam Pharmaceuticals Reports Third Quarter 2014 Financial Results and Highlights Recent Period Progress
Business Wire - Wed Nov 05, 3:00PM CST
--- Completed Phase 2 Enrollment and Initiated Phase 2 OLE Study with Revusiran (ALN-TTRsc), and Successfully Completed Non-Clinical Chronic Toxicology Studies to Enable Start of Phase 3 Trial -
ALNY: 99.33 (+3.49)
Alnylam Completes Phase 2 Enrollment and Initiates Open-Label Extension (OLE) Study with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis
Business Wire - Wed Nov 05, 7:01AM CST
--- On Track to Initiate Phase 3 Trial by Year End Following Successful Completion of Regulatory Discussions in U.S. and EU -
ALNY: 99.33 (+3.49)
Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 110.24 (-2.53), ACT: 246.34 (+0.43), PRGO: 155.99 (+0.22), ALNY: 99.33 (+3.49)
Will Humana (HUM) Miss on Earnings Estimates this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:50PM CST
Humana Inc. (HUM) is set to report third-quarter 2014 earnings results on Nov 7, 2014.
MACK: 8.60 (-0.10), MDVN: 110.24 (-2.53), ALNY: 99.33 (+3.49), HUM: 132.57 (+1.99)
Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 99.33 (+3.49), CYTX: 0.39 (-0.04), ACHN: 12.43 (+2.32), INCY: 70.09 (+0.77), SRPT: 16.05 (-0.07)
Will Actavis (ACT) Beat Earnings Estimates on Forest Deal? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:20PM CST
Actavis (ACT) is scheduled to report third-quarter 2014 results before the opening bell on Nov 5.
MNK: 92.60 (+1.54), ACT: 246.34 (+0.43), ALNY: 99.33 (+3.49), HSP: 56.13 (-0.19)
Is Hospira (HSP) Poised to Beat Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:00PM CST
Hospira (HSP), which is scheduled to report third-quarter 2014 results on Nov 6, had posted a positive earnings surprise of 28.57%.
MDVN: 110.24 (-2.53), ACT: 246.34 (+0.43), ALNY: 99.33 (+3.49), HSP: 56.13 (-0.19)
Will DaVita Healthcare (DVA) Disappoint Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 1:40PM CST
DaVita Healthcare Partners, Inc. (DVA) is set to report third-quarter 2014 earnings on Nov 6, 2014.
MDVN: 110.24 (-2.53), AMSG: 51.32 (-0.18), DVA: 74.56 (+0.07), ALNY: 99.33 (+3.49)
Alnylam Pharmaceuticals Shares Up 50.5% Since SmarTrend's Buy Recommendation (ALNY)
Comtex SmarTrend(R) - Mon Nov 03, 9:33AM CST
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on August 12th, 2014 at $61.36. In approximately 3 months, Alnylam Pharmaceuticals has returned 50.54% as of today's recent price of $92.36.
ALNY: 99.33 (+3.49)
Will Becton, Dickinson (BDX) Beat Q4 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:53PM CDT
Becton, Dickinson and Company (BDX) is set to report fourth-quarter fiscal 2014 results on Nov 4.
BDX: 127.41 (+1.87), ALNY: 99.33 (+3.49), PTN: 0.78 (+0.03), HSIC: 129.66 (+0.82)
Alnylam to Webcast Presentation at the Nomura Biotechnology Conference
Business Wire - Thu Oct 30, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Nomura Biotechnology Conference on Thursday, November 6, 2014 at 9:00 a.m. ET at the Mandarin Oriental in Boston.
ALNY: 99.33 (+3.49)
Alnylam to Webcast Conference Call Discussing Third Quarter 2014 Financial Results
Business Wire - Wed Oct 29, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the third quarter ending September 30, 2014 on Wednesday, November 5, 2014, after the U.S. financial markets close.
ALNY: 99.33 (+3.49)
Alnylam Appoints Pushkal Garg, M.D., Senior Vice President, Clinical Development
Business Wire - Wed Oct 29, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the appointment of Pushkal Garg, M.D., to the position of Senior Vice President, Clinical Development. Dr. Garg has extensive experience in clinical development across a broad range of therapeutic areas. At Alnylam, he will join the existing development team and be responsible for managing the company's clinical research, clinical operations, and biometrics functions.
ALNY: 99.33 (+3.49)
Alnylam and The Medicines Company Announce Filing of a Clinical Trial Application to Initiate a Phase 1 Study for ALN-PCSsc, an Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia
Business Wire - Tue Oct 28, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, and The Medicines Company (Nasdaq:MDCO), a global biopharmaceutical company focusing on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on the world's leading acute/intensive care hospitals, announced today that Alnylam has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1 clinical trial with ALN-PCSsc, an investigational agent for the treatment of hypercholesterolemia. ALN-PCSsc is a subcutaneously administered RNAi therapeutic targeting the gene proprotein convertase subtilisin/kexin type 9 (PCSK9), a target validated by human genetics that is involved in the metabolism of low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Per the filed CTA, the Phase 1 trial of ALN-PCSsc will be conducted in the U.K. as a randomized, single-blind, placebo-controlled, single ascending- and multi-dose study, enrolling up to 76 volunteer subjects with elevated baseline LDL-C (greater-than or equal to 100 mg/dL). Following approval of the CTA, the companies expect to initiate dosing in the Phase 1 trial in late 2014 or early 2015, with initial data expected to be reported in mid-2015.
ALNY: 99.33 (+3.49), MDCO: 24.55 (-0.04)
Recent News posted below.
Alnylam Pharmaceuticals ALNY other info.
http://investorshangout.com/Alnylam-Pharmaceu...LNY-53281/
ALNY Alnylam Pharmaceuticals Recent Headline News
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 324.30 (+3.55), ALNY: 99.33 (+3.49), ISIS: 46.25 (+1.66), OGXI: 2.15 (-0.03), TEVA: 58.03 (+0.33), RGLS: 22.84 (+0.76), GSK: 45.17 (+0.26), SNY: 46.34 (+0.65)
Alnylam to Webcast Presentation at the Credit Suisse 2014 Healthcare Conference
Business Wire - Thu Nov 06, 3:00PM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014 at 3:00 p.m. MST (5:00 p.m. EST) at the Arizona Biltmore in Phoenix, Arizona.
ALNY: 99.33 (+3.49)
Alnylam's Q3 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 11:40AM CST
Alnylam (ALNY) reported third-quarter 2014 loss of 58 cents per share, much wider than the year-ago loss of 48 cents per share.
BIIB: 324.30 (+3.55), ALNY: 99.33 (+3.49), AMAG: 34.54 (-0.41)
Investing in Socially Responsible Companies: Alnylam Pharmaceuticals, Inc.
Selena Maranjian, The Motley Fool - Motley Fool - Thu Nov 06, 9:22AM CST
Source: Alnylam Pharmaceuticals. Being a socially responsible company is not a zero-sum game, where the more socially responsible you are, the worse your financial performance is, and vice versa. Profits don't go out the window when you treat the...
ALNY: 99.33 (+3.49)
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 99.33 (+3.49), AMGN: 162.32 (+2.07), SNY: 46.34 (+0.65), REGN: 383.41 (+5.57)
Alnylam beats Street 3Q forecasts
Automated Insights - Wed Nov 05, 5:04PM CST
CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Wednesday reported a loss of $44 million in its third quarter.
ALNY: 99.33 (+3.49)
Alnylam Pharmaceuticals Reports Third Quarter 2014 Financial Results and Highlights Recent Period Progress
Business Wire - Wed Nov 05, 3:00PM CST
--- Completed Phase 2 Enrollment and Initiated Phase 2 OLE Study with Revusiran (ALN-TTRsc), and Successfully Completed Non-Clinical Chronic Toxicology Studies to Enable Start of Phase 3 Trial -
ALNY: 99.33 (+3.49)
Alnylam Completes Phase 2 Enrollment and Initiates Open-Label Extension (OLE) Study with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis
Business Wire - Wed Nov 05, 7:01AM CST
--- On Track to Initiate Phase 3 Trial by Year End Following Successful Completion of Regulatory Discussions in U.S. and EU -
ALNY: 99.33 (+3.49)
Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 110.24 (-2.53), ACT: 246.34 (+0.43), PRGO: 155.99 (+0.22), ALNY: 99.33 (+3.49)
Will Humana (HUM) Miss on Earnings Estimates this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:50PM CST
Humana Inc. (HUM) is set to report third-quarter 2014 earnings results on Nov 7, 2014.
MACK: 8.60 (-0.10), MDVN: 110.24 (-2.53), ALNY: 99.33 (+3.49), HUM: 132.57 (+1.99)
Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 99.33 (+3.49), CYTX: 0.39 (-0.04), ACHN: 12.43 (+2.32), INCY: 70.09 (+0.77), SRPT: 16.05 (-0.07)
Will Actavis (ACT) Beat Earnings Estimates on Forest Deal? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:20PM CST
Actavis (ACT) is scheduled to report third-quarter 2014 results before the opening bell on Nov 5.
MNK: 92.60 (+1.54), ACT: 246.34 (+0.43), ALNY: 99.33 (+3.49), HSP: 56.13 (-0.19)
Is Hospira (HSP) Poised to Beat Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:00PM CST
Hospira (HSP), which is scheduled to report third-quarter 2014 results on Nov 6, had posted a positive earnings surprise of 28.57%.
MDVN: 110.24 (-2.53), ACT: 246.34 (+0.43), ALNY: 99.33 (+3.49), HSP: 56.13 (-0.19)
Will DaVita Healthcare (DVA) Disappoint Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 1:40PM CST
DaVita Healthcare Partners, Inc. (DVA) is set to report third-quarter 2014 earnings on Nov 6, 2014.
MDVN: 110.24 (-2.53), AMSG: 51.32 (-0.18), DVA: 74.56 (+0.07), ALNY: 99.33 (+3.49)
Alnylam Pharmaceuticals Shares Up 50.5% Since SmarTrend's Buy Recommendation (ALNY)
Comtex SmarTrend(R) - Mon Nov 03, 9:33AM CST
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on August 12th, 2014 at $61.36. In approximately 3 months, Alnylam Pharmaceuticals has returned 50.54% as of today's recent price of $92.36.
ALNY: 99.33 (+3.49)
Will Becton, Dickinson (BDX) Beat Q4 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:53PM CDT
Becton, Dickinson and Company (BDX) is set to report fourth-quarter fiscal 2014 results on Nov 4.
BDX: 127.41 (+1.87), ALNY: 99.33 (+3.49), PTN: 0.78 (+0.03), HSIC: 129.66 (+0.82)
Alnylam to Webcast Presentation at the Nomura Biotechnology Conference
Business Wire - Thu Oct 30, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Nomura Biotechnology Conference on Thursday, November 6, 2014 at 9:00 a.m. ET at the Mandarin Oriental in Boston.
ALNY: 99.33 (+3.49)
Alnylam to Webcast Conference Call Discussing Third Quarter 2014 Financial Results
Business Wire - Wed Oct 29, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the third quarter ending September 30, 2014 on Wednesday, November 5, 2014, after the U.S. financial markets close.
ALNY: 99.33 (+3.49)
Alnylam Appoints Pushkal Garg, M.D., Senior Vice President, Clinical Development
Business Wire - Wed Oct 29, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the appointment of Pushkal Garg, M.D., to the position of Senior Vice President, Clinical Development. Dr. Garg has extensive experience in clinical development across a broad range of therapeutic areas. At Alnylam, he will join the existing development team and be responsible for managing the company's clinical research, clinical operations, and biometrics functions.
ALNY: 99.33 (+3.49)
Alnylam and The Medicines Company Announce Filing of a Clinical Trial Application to Initiate a Phase 1 Study for ALN-PCSsc, an Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia
Business Wire - Tue Oct 28, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, and The Medicines Company (Nasdaq:MDCO), a global biopharmaceutical company focusing on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on the world's leading acute/intensive care hospitals, announced today that Alnylam has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1 clinical trial with ALN-PCSsc, an investigational agent for the treatment of hypercholesterolemia. ALN-PCSsc is a subcutaneously administered RNAi therapeutic targeting the gene proprotein convertase subtilisin/kexin type 9 (PCSK9), a target validated by human genetics that is involved in the metabolism of low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Per the filed CTA, the Phase 1 trial of ALN-PCSsc will be conducted in the U.K. as a randomized, single-blind, placebo-controlled, single ascending- and multi-dose study, enrolling up to 76 volunteer subjects with elevated baseline LDL-C (greater-than or equal to 100 mg/dL). Following approval of the CTA, the companies expect to initiate dosing in the Phase 1 trial in late 2014 or early 2015, with initial data expected to be reported in mid-2015.
ALNY: 99.33 (+3.49), MDCO: 24.55 (-0.04)
(0)
(0)